Merrill Goozner, a former editor of Modern Healthcare, publishes GoozNews the Substack where this article originally appeared.
Why Biogen’s medication, aducanumab, should get studied through an important part of the Affordable Care Act, the Patient Centers Outcomes Research Institute.
Public option proponents face huge political hurdles; there is another way to achieve many of the same goals.
The president abandons the long-held view that innovation requires high prices.
An insightful new history of the Affordable Care Act—and the fight to save it—points to a difficult road ahead for insuring Americans.
Until advocates are willing to take on Big Pharma, reform efforts have no chance.